Top Shipping Stocks To Buy Right Now

Top Shipping Stocks To Buy Right Now: Novo Nordisk A/S (NVO)

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products in Denmark and internationally. The company operates in two segments, Diabetes Care and Biopharmaceuticals. The Diabetes care segment covers insulins, oral antidiabetic drugs, and other protein-related products and projects comprising glucagon and protein-related delivery systems, as well as GLP-1 analogue. The Biopharmaceuticals segment provides products in the areas of haemophilia, growth hormone therapy, hormone replacement therapy, and inflammation therapy. Its products are marketed and distributed through subsidiaries, distributors, and independent agents in 180 countries. Novo Nordisk A/S has a collaboration agreement with Archimedes, Inc. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

Advisors' Opinion:

• [By Sheila Dang]

  Halozyme's return on equity and assets are consistently in the red, ending at about -109% in return on equity in 2012, and -82% in return on assets in 2013. The company's competitors in biotechnology, such as Novo Nordisk (NVO) and Amgen Inc. (AMGN), post much more favorable return percentages. Yet, Halozyme's revenue, EBITDA and EPS growth percentages are much higher than the industry median, with Halozyme's revenue growth being higher than 97% of the global biotechnology industry.

• [By Ben Levisohn]

  We continue to argue Sanofi offers near term momentum. This is based on scope for pipeline expectations to rise (today's news on Dengue vaccine and recent PCSK9 data should help), coupled with an attractive valuation and earnings upside risk going into Q3. Sanofi trades at a >10% PE discount to the sector yet offers comparable growth (5YR EPS CAGR 10%). That said, we retain our Neutral rating as ! we have higher conviction on the LT fundamentals elsewhere in the sector, and remain concerned about the sustainability of growth for the diabetes franchise (>30% of profits) post 2017. Preferred Pharma plays include AstraZeneca (AZN), Bayer, Novo Nordisk (NVO) and UCB. Bristol-Myers Squibb (BMY) and Pfizer (PFE) are our preferred US plays.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-shipping-stocks-to-buy-right-now-4.html